Anti-vista antibodies and fragments
The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
1. A method for treating cancer in a subject in need thereof, said method comprising administering to the subject an effective amount of an antibody or antibody fragment, which antibody comprises a VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and which further comprises a VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO: 29 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 30.
2. A method for suppressing tumor growth in a subject in need thereof, said method comprising administering to the subject an effective amount of an antibody or antibody fragment, which antibody comprises a VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and which further comprises a VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO: 29 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 30.
3. A method for eliciting a biological response in a subject in need thereof, said method comprising administering to the subject an effective amount of an antibody or antibody fragment, which antibody comprises a VH domain comprising a VH CDR1 having the amino acid sequence of SEQ ID NO: 25, a VH CDR2 having the amino acid sequence of SEQ ID NO:26 and a VH CDR3 having the amino acid sequence of SEQ ID NO:27, and which further comprises a VL domain comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:28, a VL CDR2 having the amino acid sequence of SEQ ID NO: 29 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 30, thereby enhancing an immune response, wherein the biological response comprises one or more of:
(a) activation of monocytes;
(b) induction of T-cell proliferation and cytokine secretion;
(c) increased survival of monocytes;
(d) induction of antibody-dependent cell-mediated cytotoxicity (ADCC) in cells-expressing VISTA; and
(e) induction of antibody-dependent cellular phagocytosis (ADCP) in cells-expressing VISTA.
4. The method of claim 1 , wherein the antibody or antibody fragment is administered at least one of:
(i) parenterally or nonparenterally;
(ii) in a dosage range of 0.1-15 mg/kg per administration;
(iii) weekly, once every two weeks, once every three weeks, once every month, once every 2 months, or once every 3 months.
5. The method of claim 1 , wherein the subject is human.
6. The method of claim 1 , wherein the cancer is a leukemia, a lymphoma, a myelodysplastic syndrome, a myeloma, or a combination thereof; or a solid tumor.
7. The method of claim 6 , wherein the leukemia is acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid (myelogenous) leukemia (AML), chronic myelogenous leukemia (CML), hairy cell leukemia, T-cell prolymphocytic leukemia, large granular lymphocytic leukemia, or adult T-cell leukemia.
8. The method of claim 6 , wherein the solid tumor:
(i) is surrounded by a tumor stroma comprising myeloid cells, T-cells, or a combination of myeloid cells and T-cells;
(ii) is infiltrated with myeloid cells, T cells or a combination of myeloid cells and T-cells; and/or
(iii) is lung cancer.
9. The method of claim 8 , wherein the lung cancer is a non-small cell lung carcinoma (NSCLC).
10. The method of claim 1 , further comprising administering a second treatment or therapeutic.
11. The method of claim 10 , wherein the second treatment or therapeutic is a vaccine, surgery, chemotherapy, radiation therapy, biologic therapy, targeted therapy, immunomodulatory therapy, or a combination thereof.
12. The method of claim 2 , wherein the antibody or antibody fragment is administered at least one of:
(i) parenterally or nonparenterally;
(ii) in a dosage range of 0.1-15 mg/kg per administration; and/or
(iii) weekly, once every two weeks, once every three weeks, once every month, once every 2 months, or once every 3 months.
13. The method of claim 2 , wherein the subject is human.
14. The method of claim 2 , wherein the cancer is a leukemia, a lymphoma, a myelodysplastic syndrome, a myeloma, or a combination thereof;
or a solid tumor.
15. The method of claim 14 , wherein the leukemia is acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid (myelogenous) leukemia (AML), chronic myelogenous leukemia (CML), hairy cell leukemia, T-cell prolymphocytic leukemia, large granular lymphocytic leukemia, or adult T-cell leukemia.
16. The method of claim 14 , wherein the solid tumor:
(i) is surrounded by a tumor stroma comprising myeloid cells, T-cells, or a combination of myeloid cells and T-cells;
(ii) is infiltrated with myeloid cells, T cells or a combination of myeloid cells and T-cells; and/or
(iii) is lung cancer.
17. The method of claim 16 , wherein the lung cancer is a non-small cell lung carcinoma (NSCLC).
18. The method of claim 2 , further comprising administering a second treatment or therapeutic.
19. The method of claim 18 , wherein the second treatment or therapeutic is a vaccine, surgery, chemotherapy, radiation therapy, biologic therapy, targeted therapy, immunomodulatory therapy, or a combination thereof.
20. The method of claim 3 , wherein the immune response is an antitumor immune response.
21. The method of claim 1 , wherein the antibody comprises a variable heavy chain polypeptide at least 90% identical to SEQ ID NO:37 and a variable light chain polypeptide at least 90% identical to SEQ ID NO:44.
22. The method of claim 2 , wherein the antibody comprises a variable heavy chain polypeptide at least 90% identical to SEQ ID NO:37 and a variable light chain polypeptide at least 90% identical to SEQ ID NO:44.
23. The method of claim 3 , wherein the antibody comprises a variable heavy chain polypeptide at least 90% identical to SEQ ID NO:37 and a variable light chain polypeptide at least 90% identical to SEQ ID NO:44.
24. The method of claim 1 , wherein the antibody comprises a variable heavy chain polypeptide having the sequence of SEQ ID NO:37 and a variable light chain polypeptide having the sequence of SEQ ID NO:44.
25. The method of claim 2 , wherein the antibody comprises a variable heavy chain polypeptide having the sequence of SEQ ID NO:37 and a variable light chain polypeptide having the sequence of SEQ ID NO:44.
26. The method of claim 3 , wherein the antibody comprises a variable heavy chain polypeptide having the sequence of SEQ ID NO:37 and a variable light chain polypeptide having the sequence of SEQ ID NO:44.
27. The method of claim 1 , wherein the antibody or antibody fragment thereof comprises a human IgG1 constant region.
28. The method of claim 2 , wherein the antibody or antibody fragment thereof comprises a human IgG1 constant region.
29. The method of claim 3 , wherein the antibody or antibody fragment thereof comprises a human IgG1 constant region.
30. The method of claim 21 , wherein the antibody or antibody fragment comprises the heavy chain of SEQ ID NO:61 and the light chain of SEQ ID NO:56.
31. The method of claim 22 , wherein the antibody or antibody fragment comprises the heavy chain of SEQ ID NO:61 and the light chain of SEQ ID NO:56.
32. The method of claim 23 , wherein the antibody or antibody fragment comprises the heavy chain of SEQ ID NO:61 and the light chain of SEQ ID NO:56.